Carlos A DiazGranados

Summary

Affiliation: Sanofi Pasteur

Publications

  1. doi request reprint Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty
    Carlos A DiazGranados
    Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA 18370, United States Electronic address
    Vaccine 33:4565-71. 2015
  2. doi request reprint Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines
    Carlos A DiazGranados
    Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA 18370, USA Electronic address
    Vaccine 33:4988-93. 2015
  3. doi request reprint Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age
    Carlos A DiazGranados
    Sanofi Pasteur, Inc, Swiftwater, PA, USA Electronic address
    Vaccine 33:7188-93. 2015
  4. doi request reprint High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season
    Carlos A DiazGranados
    Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA 18370, USA
    Vaccine 31:861-6. 2013
  5. doi request reprint Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials
    Carlos A DiazGranados
    Sanofi Pasteur, Swiftwater, PA 18370, USA
    Vaccine 31:49-57. 2012
  6. pmc Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults
    Carlos A DiazGranados
    Sanofi Pasteur, Swiftwater, Pennsylvania
    Clin Infect Dis 62:1092-9. 2016
  7. pmc Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial
    Andrew J Dunning
    Sanofi Pasteur, Swiftwater, Pennsylvania, USA
    Clin Vaccine Immunol 23:228-35. 2016
  8. ncbi request reprint FluzoneĀ® High-Dose Influenza Vaccine
    Corwin A Robertson
    a Sanofi Pasteur Inc, Swiftwater, PA, USA
    Expert Rev Vaccines 15:1495-1505. 2016

Collaborators

  • David P Greenberg
  • Corwin A Robertson
  • Andrew J Dunning
  • Victoria A Landolfi
  • Ayman Chit
  • H Keipp Talbot
  • Timothy Voloshen
  • Branda Hu
  • Michael D Decker
  • Monica Mercer

Detail Information

Publications8

  1. doi request reprint Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty
    Carlos A DiazGranados
    Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA 18370, United States Electronic address
    Vaccine 33:4565-71. 2015
    ..To evaluate the consistency of IIV-HD benefits, supplemental analyses explored efficacy and immunogenicity by baseline characteristics of special interest...
  2. doi request reprint Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines
    Carlos A DiazGranados
    Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA 18370, USA Electronic address
    Vaccine 33:4988-93. 2015
    ..Here we evaluate the effectiveness of IIV-HD compared to IIV-SD in preventing serious illnesses considered potential sequelae or complications of influenza infection...
  3. doi request reprint Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age
    Carlos A DiazGranados
    Sanofi Pasteur, Inc, Swiftwater, PA, USA Electronic address
    Vaccine 33:7188-93. 2015
    ..The current study examined whether a high-dose inactivated trivalent influenza vaccine (IIV3-HD) might improve immune responses over a standard-dose inactivated influenza vaccine (IIV3-SD) in this age group...
  4. doi request reprint High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season
    Carlos A DiazGranados
    Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA 18370, USA
    Vaccine 31:861-6. 2013
    ..High-dose trivalent influenza vaccine was developed to improve antibody responses to influenza vaccine in the elderly and hence potentially impact favorably on influenza-associated morbidity and mortality in this population...
  5. doi request reprint Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials
    Carlos A DiazGranados
    Sanofi Pasteur, Swiftwater, PA 18370, USA
    Vaccine 31:49-57. 2012
    ..The true level of influenza vaccine efficacy is controversial and many factors may influence its estimation...
  6. pmc Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults
    Carlos A DiazGranados
    Sanofi Pasteur, Swiftwater, Pennsylvania
    Clin Infect Dis 62:1092-9. 2016
    ..IIV-HD improved efficacy relative to IIV-SD in a randomized controlled trial. Recent observational studies suggest that previous influenza vaccination may influence the immunogenicity and effectiveness of current-season vaccination...
  7. pmc Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial
    Andrew J Dunning
    Sanofi Pasteur, Swiftwater, Pennsylvania, USA
    Clin Vaccine Immunol 23:228-35. 2016
    ..This study has been registered at ClinicalTrials.gov under registration no. NCT01427309.)...
  8. ncbi request reprint FluzoneĀ® High-Dose Influenza Vaccine
    Corwin A Robertson
    a Sanofi Pasteur Inc, Swiftwater, PA, USA
    Expert Rev Vaccines 15:1495-1505. 2016
    ..Further investigation of IIV3-HD vaccination as a way to improve immune responses and protection against influenza in immunocompromised individuals is warranted...